Status:
TERMINATED
Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Children's Hospital of Philadelphia
Conditions:
Carotid Artery Disease
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Lay abstract: Study Purpose With contemporary combined modality therapy the expected longterm survival of children and adolescents with Hodgkin's disease (HD) is exceedingly high. Thus, the emphasis f...
Detailed Description
With contemporary combined modality therapy the expected longterm survival of children and adolescents with Hodgkin's disease (HD) is exceedingly high. Thus, the emphasis for future therapeutic interv...
Eligibility Criteria
Inclusion
- At least three years from completion of treatment for Hodgkin's Disease
- Age 18- 35
- Ability to complete self report questionnaires in either English or Spanish
- Willingness of patient, or parent/guardian if patient less than 18 years of age to sign consent to participate in study
- Willingness of patient to sign assent if greater than 7 years of age and less than 18 years
Exclusion
- Pregnant or breast feeding
- Tanner Stage 1
- Currently taking cyclosporine, niacin, antiretrovirals, macrolide antibiotic, azole antifungal
- Liver enzymes greater than 1.5 times the upper level of normal
- Creatine Kinase greater than 2 times the upper level of normal
- Use of estrogen containing contraceptive
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00746603
Start Date
January 1 2008
End Date
July 1 2009
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia Univeristy Medical Center
New York, New York, United States, 10032